Grant name: Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk
Funding organization: National Institutes of Health (NIH)
Total funding amount: Not specified
Duration: Up to 5 years
Primary objective: To elucidate how HIV-induced immunometabolic alterations impact immune response and increase risk for TB or HBV.
Key stakeholders: Public and private nonprofit institutions, individuals, and various organizations.
Funding source: NIH
Funding type: Grant
Significance: Addresses critical health issues related to HIV, TB, and HBV.
Grant frequency: New opportunity
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Special District Governments
Indian/Native American Tribal Governments (Federally Recognized and Other)
Federal Governments
U.S. Territory or Possession
Other (e.g., Independent School Districts, Public Housing Authorities, Faith-based Organizations, Regional Organizations, Foreign Organizations)
Support hypothesis-driven basic, preclinical, and translational laboratory research.
Focus on immunometabolic alterations during HIV infection that increase risk of TB or HBV.
Encourage interdisciplinary teams and innovative approaches such as machine learning.
Applications must not propose clinical trials.
Preliminary data should support hypotheses.
Utilization of existing clinical samples is encouraged.
Application budgets are not limited but must reflect actual project needs.
Open Date: April 07, 2025
Earliest Start Date: May 07, 2025
Expiration Date: January 08, 2028
Must comply with NIH Grants Policy Statement and federal regulations.
Applications must be submitted electronically via Grants.gov.
Follow instructions in the Research (R) Instructions in the How to Apply - Application Guide.